Bulletin
Investor Alert

Market Pulse Archives

March 5, 2021, 7:38 a.m. EST

Moderna, via Takeda, seeks authorization for COVID-19 vaccine in Japan

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Moderna Inc. (MRNA)
  • X
    Takeda Pharmaceutical Co. Ltd. (4502)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Moderna Inc. /zigman2/quotes/205619834/composite MRNA +6.84% were down 0.9% in premarket trading on Friday after the company said it is pursuing approval for its COVID-19 vaccine in Japan in partnership with Takeda Pharmaceutical Co. /zigman2/quotes/201302442/delayed JP:4502 -0.30% . Takeda submitted the new drug application and will be tasked with importing and distributing the vaccine from the Cambridge, Mass.-based company. Takeda is also conducting the Phase 1/2 trial of the vaccine in adults who are at least 20 years old there; enrollment ended in February. If approved, Takeda will distribute 50 million doses of Moderna's two-dose vaccine in Japan in the first half of 2021. Shares of Moderna have rallied 372.3% over the past 12 months, while the broader S&P 500 /zigman2/quotes/210599714/realtime SPX +0.36% is up 20.4%.

/zigman2/quotes/205619834/composite
US : U.S.: Nasdaq
$ 170.81
+10.94 +6.84%
Volume: 19.04M
April 16, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$63.98 billion
Rev. per Employee
$617,996
loading...
/zigman2/quotes/201302442/delayed
JP : Japan: Tokyo
¥ 3,704.00
-11.00 -0.30%
Volume: 4.48M
April 16, 2021 3:00p
P/E Ratio
32.24
Dividend Yield
4.86%
Market Cap
¥5813.30 billion
Rev. per Employee
¥69.30M
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,185.47
+15.05 +0.36%
Volume: 2.21B
April 16, 2021 5:15p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.